Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

The Single Most Important Metric For Moderna Stock

Company update Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Moderna raised its 2026 total revenue growth outlook to 15% to 25%, up from a previous expectation of up to 10%, driven by strong international performance.

🌍 International revenue reached $900 million in the first nine months of 2026, exceeding the company's full-year 2025 total and representing about 40% of Q3 sales.

πŸ’° The company reported an operating profit of $0.13 billion in Q3 2026, a turnaround from a $0.26 billion loss in the same quarter last year.

πŸ“‰ Cash flow remains negative with a $1.56 billion outflow in Q3 due to a $950 million litigation settlement payment and seasonal working capital swings.

πŸ₯ U.S. domestic COVID-19 vaccination momentum is trending flat year over year through late October, potentially limiting domestic revenue growth.

πŸ’΅ Moderna ended the quarter with $8 billion in cash and investments, supported by $2.6 billion in net proceeds from a convertible note issuance.

⚠️ Investors are concerned about Q4 seasonality which may reduce revenue as shipments between quarters shift, potentially offsetting recent third-quarter strength.

πŸ“… Earnings for the full year 2026 are expected to be reported in February 2027, with a focus on whether overseas growth can sustain the raised guidance.

πŸ“‰ The stock declined 7% during an Analyst Day session on November 12, indicating market skepticism regarding the company's current valuation relative to its financial losses.

Bullish Signals
  • Management raised its 2026 revenue growth outlook to 15% to 25%, driven by durable international partnerships in the U.K., Canada, and Australia.
  • International revenue reached $900 million in the first nine months of 2026, surpassing the company's entire 2025 total sales.
  • The company achieved an operating profit of $0.13 billion in Q3 2026, marking a significant turnaround from a $0.26 billion loss in the same quarter last year.
  • Moderna secured $8 billion in cash and investments at quarter-end, bolstered by $2.6 billion in net proceeds from a convertible note to fund operations.
Risk Factors
  • The company reported a twelve-month operating loss of $2.93 billion, which includes a significant $900 million litigation settlement charge.
  • Cash flow from operations was an outflow of $1.56 billion in Q3 2026 due to the large litigation payment and seasonal working capital swings.
  • U.S. domestic COVID-19 vaccination momentum is trending flat year over year, limiting potential revenue growth in the home market.
  • Revenue seasonality poses a risk as Q4 shipments may be lower than Q3, potentially offsetting recent third-quarter strength and impacting full-year guidance.
Full Analysis
Moderna (MRNA) is facing a valuation contradiction where its stock trades at 36.8 times sales despite reporting a $2.93 billion operating loss over the last twelve months, which includes a $900 million litigation settlement charge. The company's primary growth driver has shifted to international markets, with revenue outside the U.S. reaching $900 million in the first nine months of 2026, surpassing its entire 2025 total. Management raised its full-year 2026 revenue growth outlook to between 15% and 25%, citing durable overseas partnerships in the U.K., Canada, and Australia. While international sales now account for approximately 40% of third-quarter revenue, domestic COVID-19 vaccination momentum in the U.S. retail and long-term care channels is trending flat year over year through late October. Financial performance remains mixed with a shift from loss to profit; Moderna recorded an operating profit of $0.13 billion in the third quarter of 2026 compared to a $0.26 billion loss a year prior, though it still posted a twelve-month operating loss on $2.52 billion in revenue. Cash flow challenges persist with an outflow of $1.56 billion from operations in Q3 due to working capital swings and the litigation payment, although the company holds $8 billion in cash and investments bolstered by recent convertible note proceeds. Analysts are closely watching Q4 results for potential seasonality adjustments that could offset Q3 strength, with earnings expected in February 2027. The stock fell 7% following an Analyst Day on November 12, reflecting investor caution regarding the sustainability of overseas growth and the company's transition from a pandemic-focused entity to a diversified biopharma player.